Phase 2 Ovarian Cancer Trial, Not Yet Recruiting
voxsanity.com.au · Eligibility summary from public government registries · 18 August 2026 · not medical advice
Who may and may not be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who may be able to join
- People with recurrent, advanced, or metastatic ovarian or endometrial cancer that got worse during or after standard treatment.
- People aged 18 years or older.
- People with a general health and activity level rated 0 or 1 on a standard medical scale (meaning fully active or able to carry out light work — confirm with trial site).
- People who are able to understand the study information and are willing to sign a consent form.
- People whose cancer can be measured or detected by scans, or who have cancer-related fluid build-up in the chest or abdomen, or disease that does not meet standard measurement criteria.
- People who test negative on a blood pregnancy test taken within 48 hours before starting treatment, where this test is required.
- People with adequate bone marrow function (confirm with trial site for specific values).
- People with adequate liver function (confirm with trial site for specific values).
- People with adequate kidney function, based on specific blood or calculated measurements falling within acceptable ranges.
- People who have fully recovered from any recent surgery, with at least 1 week since a minor surgery or at least 21 days since a major surgery before starting treatment, and whose surgery-related side effects have resolved to a mild level or better.
- People for whom at least 28 days have passed since their last cancer or hormonal treatment before starting the study drug BMX-001.
Who may not be able to join
Each point below is a reason the trial team may not be able to accept someone. It is not a list of requirements to meet.
- People with ongoing moderate nerve damage (Grade 2 peripheral neuropathy) remaining from prior treatment.
- People with untreated cancer that has spread to the brain or spinal cord, or people who need more than 10 mg per day of prednisone (or equivalent) to manage brain/spinal involvement, or people who have had signs of neurological instability within the past 28 days.
- People currently receiving other active cancer treatments or other experimental treatments for their cancer.
- People who have previously received weekly paclitaxel treatment for recurrent disease.
- People with significant heart disease.
- People with a history of, or current, brain or nervous system conditions unrelated to cancer that are not well controlled with standard treatment (such as uncontrolled seizures).
- People with a wound, ulcer, or bone fracture that has not healed.
- People who have had a serious active infection requiring intravenous antibiotics or hospitalisation within 7 days before joining the study.
- People with a known severe allergy or serious hypersensitivity reaction to any of the study drugs or their ingredients, including certain types of proteins used in medicines or products containing a specific ingredient called Cremophor EL.
- People who regularly need blood transfusions, platelet transfusions, or injections to boost white blood cell counts.
- Women of childbearing potential who are unwilling to use a highly effective form of contraception, or to abstain from sex, during treatment and for 6 months after the last dose of study drug.
- Women who are pregnant or breastfeeding.
- People who have any other condition that, in the treating doctor's opinion, could increase risks, affect the study results, or make participation unsuitable.
- People who have previously received BMX-001 or participated in another study involving BMX-001.
- People with a history of additional risk factors for a specific type of heart rhythm problem called Torsades de Pointes (for example, heart failure, low potassium levels, or a family history of Long QT Syndrome).
- People with severe, active serious health conditions as defined in the study protocol (confirm with trial site for specific details).
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: James Crapo, MD, BioMimetix JV, LLC
Phone: 610-308-6640
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
To determine the Recommended Phase 2 Dose of BMX-001 in combination with paclitaxel in a safety cohort of patients. This would be carried forward as the dose to be used in the expanded cohort portion of the trial.
Can't join this trial?
Data last synced from ClinicalTrials.gov: 23 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.